{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:19:13Z","timestamp":1777907953213,"version":"3.51.4"},"reference-count":140,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Checkmate"},{"name":"Castle Biosciences, Inc."},{"name":"Immunocore LLC"},{"name":"Iovance"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.hoc.2020.09.003","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T09:21:23Z","timestamp":1603704083000},"page":"1-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["State of Melanoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Lilit","family":"Karapetyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/1097-0142(196605)19:5<607::AID-CNCR2820190502>3.0.CO;2-8","article-title":"On the antiquity of melanoma","volume":"19","author":"Urteaga","year":"1966","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.003_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CMR.0b013e328351fa4d","article-title":"A\u00a0brief history of melanoma: from mummies to mutations","volume":"22","author":"Rebecca","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.hoc.2020.09.003_bib3","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2018) (www.seer.cancer.gov\/popdata), National Cancer Institute, DCCPS, Surveillance Research Program, released December 2019."},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib4","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib5","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00000658-197010000-00018","article-title":"Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy","volume":"172","author":"Morton","year":"1970","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib6","first-page":"233","article-title":"Demonstration of antibodies against human malignant melanoma by immunofluorescence","volume":"64","author":"Morton","year":"1968","journal-title":"Surgery"},{"key":"10.1016\/j.hoc.2020.09.003_bib7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/1097-0142(196001\/02)13:1<79::AID-CNCR2820130115>3.0.CO;2-4","article-title":"Spontaneous regression of human melanoma: clinical and experimental studies","volume":"13","author":"Sumner","year":"1960","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","article-title":"BCG immunotherapy of malignant melanoma: summary of a seven-year experience","volume":"180","author":"Morton","year":"1974","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib9","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1984.2.4.336","article-title":"Interferons in the treatment of human cancer","volume":"2","author":"Kirkwood","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.003_bib10","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2020.09.003_bib11","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"9633","key":"10.1016\/j.hoc.2020.09.003_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"issue":"4257","key":"10.1016\/j.hoc.2020.09.003_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in\u00a0vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.003_bib14","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2020.09.003_bib15","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J Sci Am"},{"issue":"34","key":"10.1016\/j.hoc.2020.09.003_bib16","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1200\/JCO.2007.12.0253","article-title":"Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients","volume":"25","author":"Ives","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.003_bib17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2007.11.9941","article-title":"Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group","volume":"26","author":"Testori","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.hoc.2020.09.003_bib18","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2012.47.9303","article-title":"Adjuvant ganglioside GM2-KLH\/QS-21 vaccination versus observation after resection of primary tumor\u00a0> 1.5\u00a0mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial","volume":"31","author":"Eggermont","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib19","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1200\/JCO.2002.08.071","article-title":"Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group","volume":"20","author":"Sondak","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000658-199210000-00010","article-title":"Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine","volume":"216","author":"Morton","year":"1992","journal-title":"Ann Surg"},{"issue":"18_suppl","key":"10.1016\/j.hoc.2020.09.003_bib21","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1200\/jco.2007.25.18_suppl.8508","article-title":"An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites","volume":"25","author":"Morton","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","article-title":"The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?","volume":"17","author":"Slingluff","year":"2011","journal-title":"Cancer J"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib23","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.suc.2014.07.005","article-title":"Melanoma vaccines: mixed past, promising future","volume":"94","author":"Ozao-Choy","year":"2014","journal-title":"Surg Clin North Am"},{"issue":"22","key":"10.1016\/j.hoc.2020.09.003_bib24","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2020.09.003_bib25","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1093\/annonc\/mdw291","article-title":"Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)","volume":"27","author":"Saiag","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.09.003_bib26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12967-015-0572-3","article-title":"Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting","volume":"13","author":"Lipson","year":"2015","journal-title":"J\u00a0Transl Med"},{"issue":"5256","key":"10.1016\/j.hoc.2020.09.003_bib27","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.hoc.2020.09.003_bib28","series-title":"Eight cases of Melanosis with pathological and therapeutical remarks on that disease","author":"Norris","year":"1857"},{"key":"10.1016\/j.hoc.2020.09.003_bib29","series-title":"The First Lines of the Theory and Practice of Surgery","author":"Cooper","year":"1840"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/archsurg.1991.01410280036004","article-title":"Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma","volume":"126","author":"Veronesi","year":"1991","journal-title":"Arch Surg"},{"issue":"18","key":"10.1016\/j.hoc.2020.09.003_bib31","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJM198805053181804","article-title":"Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3\u00a0cm","volume":"318","author":"Veronesi","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.003_bib32","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/1097-0142(20001001)89:7<1495::AID-CNCR12>3.0.CO;2-D","article-title":"Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0\u00a0mm","volume":"89","author":"Cohn-Cedermark","year":"2000","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib33","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/cncr.11272","article-title":"Surgical margins in cutaneous melanoma (2\u00a0cm versus 5\u00a0cm for lesions measuring less than 2.1-mm thick)","volume":"97","author":"Khayat","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.003_bib34","first-page":"101","article-title":"Long-term results of a prospective surgical trial comparing 2\u00a0cm vs. 4\u00a0cm excision margins for 740 patients with 1-4\u00a0mm melanomas","volume":"8","author":"Balch","year":"2001","journal-title":"Ann Surg Oncol"},{"issue":"9803","key":"10.1016\/j.hoc.2020.09.003_bib35","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","article-title":"2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2\u00a0mm: a randomised, multicentre trial","volume":"378","author":"Gillgren","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.003_bib36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(15)00482-9","article-title":"Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial","volume":"17","author":"Hayes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMoa030681","article-title":"Excision margins in high-risk malignant melanoma","volume":"350","author":"Thomas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.003_bib38","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/jamadermatol.2019.2346","article-title":"Evolution of Excisional Surgery Practices for Melanoma in the United States","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.003_bib39","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/jamadermatol.2019.2890","article-title":"Comparison of survival after Mohs micrographic surgery vs wide margin excision for early-stage invasive melanoma","volume":"155","author":"Cheraghlou","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.hoc.2020.09.003_bib40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1245\/ASO.2004.02.031","article-title":"Dr. Herbert Lumley Snow, MD, MRCS (1847-1930): the original champion of elective lymph node dissection in melanoma","volume":"11","author":"Neuhaus","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"9105","key":"10.1016\/j.hoc.2020.09.003_bib41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(97)08260-3","article-title":"Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial","volume":"351","author":"Cascinelli","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"issue":"13","key":"10.1016\/j.hoc.2020.09.003_bib43","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1245\/s10434-016-5137-z","article-title":"Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis","volume":"23","author":"Cordeiro","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.003_bib44","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hoc.2020.09.003_bib45","first-page":"02362","article-title":"Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia Nomogram","volume":"19","author":"Lo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.003_bib46","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1999.17.3.976","article-title":"Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients","volume":"17","author":"Gershenwald","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2020.09.003_bib47","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-Node Biopsy or Nodal Observation in Melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1\u20132","key":"10.1016\/j.hoc.2020.09.003_bib48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/ans.13526","article-title":"Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma","volume":"87","author":"Theodore","year":"2017","journal-title":"ANZ J Surg"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib49","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/SLA.0b013e318161312a","article-title":"Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma","volume":"247","author":"Guggenheim","year":"2008","journal-title":"Ann Surg"},{"issue":"23","key":"10.1016\/j.hoc.2020.09.003_bib50","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"32","key":"10.1016\/j.hoc.2020.09.003_bib51","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Leiter","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.003_bib52","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/bjs.9502","article-title":"Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis","volume":"101","author":"Glover","year":"2014","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/028418601750071091","article-title":"Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin--an analysis of survival and local recurrence","volume":"40","author":"Kretschmer","year":"2001","journal-title":"Acta Oncol"},{"issue":"36","key":"10.1016\/j.hoc.2020.09.003_bib54","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2020.09.003_bib55","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2020.09.003_bib56","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.003_bib57","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2020.09.003_bib58","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.003_bib59","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/1097-0142(197212)30:6<1457::AID-CNCR2820300607>3.0.CO;2-5","article-title":"Therapy of malignant melanoma with an imidazole carboxamide and bis-chloroethyl nitrosourea","volume":"30","author":"Costanza","year":"1972","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.003_bib60","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4","article-title":"Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)","volume":"53","author":"Hill","year":"1984","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib61","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ctrv.2007.06.004","article-title":"Treatments for metastatic melanoma: synthesis of evidence from randomized trials","volume":"33","author":"Lui","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"10.1016\/j.hoc.2020.09.003_bib62","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.003_bib63","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1093\/annonc\/mdv324","article-title":"A\u00a0randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-na\u00efve patients with metastatic melanoma","volume":"26","author":"Hersh","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib64","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib65","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1200\/JCO.1994.12.5.1036","article-title":"Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside","volume":"12","author":"Livingston","year":"1994","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2020.09.003_bib66","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.2015.63.3776","article-title":"Final results of the sunbelt melanoma trial: a multi-institutional prospective randomized phase iii study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy","volume":"34","author":"McMasters","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib67","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/JCO.2016.70.2951","volume":"35","author":"Agarwala","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.003_bib68","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1470-2045(10)70288-6","article-title":"Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial","volume":"12","author":"Hansson","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx133","article-title":"Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy","volume":"110","author":"Suciu","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib70","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","article-title":"Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities","volume":"6","author":"Jonasch","year":"2001","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.003_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.09.003_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline","author":"Seth","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11 Pt 1","key":"10.1016\/j.hoc.2020.09.003_bib73","first-page":"4420","article-title":"Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor","volume":"41","author":"Lotze","year":"1981","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.hoc.2020.09.003_bib74","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.003_bib75","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1002\/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z","article-title":"Clinical effects and toxicity of interleukin-2 in patients with cancer","volume":"58","author":"Lotze","year":"1986","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.003_bib76","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/1097-0142(19941215)74:12<3212::AID-CNCR2820741221>3.0.CO;2-I","article-title":"Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma","volume":"74","author":"White","year":"1994","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.003_bib77","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1200\/JCO.1994.12.12.2714","article-title":"Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma","volume":"12","author":"Guleria","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib78","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/1097-0142(19950215)75:4<1030::AID-CNCR2820750420>3.0.CO;2-5","article-title":"The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma","volume":"75","author":"MacFarlane","year":"1995","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib79","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","article-title":"Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer","volume":"83","author":"Kammula","year":"1998","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.003_bib80","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jso.23702","article-title":"Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review","volume":"110","author":"Byers","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib81","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2020.09.003_bib82","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.hoc.2020.09.003_bib83","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib84","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","article-title":"Ipilimumab 10\u00a0mg\/kg versus ipilimumab 3\u00a0mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial","volume":"18","author":"Ascierto","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib85","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib86","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2020.09.003_bib88","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.09.003_bib89","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2018.36.15_suppl.9503","article-title":"4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006","volume":"36","author":"Long","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib90","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1001\/jamaoncol.2020.2288","article-title":"Association of BRAF V600E\/K Mutation Status and Prior BRAF\/MEK inhibition with pembrolizumab outcomes in advanced melanoma: pooled analysis of 3 clinical trials","volume":"6","author":"Puzanov","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib91","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.003_bib92","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib93","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.09.003_bib94","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1200\/JCO.2019.37.15_suppl.9501","article-title":"Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)","volume":"37","author":"Tawbi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib95","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.09.003_bib96","first-page":"2020","article-title":"Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial","volume":"38","author":"Daniel Olson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.hoc.2020.09.003_bib97","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6892","key":"10.1016\/j.hoc.2020.09.003_bib98","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.003_bib99","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.003_bib100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.2012.42.1529","article-title":"Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma","volume":"31","author":"Flaherty","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2020.09.003_bib101","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1158\/1078-0432.CCR-07-4123","article-title":"A\u00a0Phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel","volume":"14","author":"Flaherty","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2020.09.003_bib102","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.hoc.2020.09.003_bib103","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9839","key":"10.1016\/j.hoc.2020.09.003_bib104","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in <em>BRAF<\/em>-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.003_bib105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2020.09.003_bib106","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK Inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9992","key":"10.1016\/j.hoc.2020.09.003_bib107","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2020.09.003_bib109","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2020.09.003_bib110","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.09.003_bib111","unstructured":"McArthur GA DB, Larkin J, et\u00a0al. 5-year survival update of cobimetinib plus vemurafenib BRAF V600 mutation-positive advanced melanoma: final analysis of the coBRIM study. Presented at: the 16th International Congress of the Society for Melanoma Research; November 20\u201323, 2019; Salt Lake City, UT."},{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib112","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with <em>BRAF<\/em>-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 5","key":"10.1016\/j.hoc.2020.09.003_bib113","first-page":"1215OA","article-title":"Results of COLUMBUS part 2: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma","volume":"28","author":"Dummer","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib114","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.003_bib115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.hoc.2020.09.003_bib116","doi-asserted-by":"crossref","unstructured":"McArthur GA, Stroyakovskiy D, Gogas H, et\u00a0al. CT012 \u2014 Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: primary results from the phase 3 IMspire150 trial. Presented at: the 2020 AACR Annual Virtual Meeting I; April 27\u201328, 2020 Abstract CT012. 2020.","DOI":"10.1158\/1538-7445.AM2020-CT012"},{"issue":"10240","key":"10.1016\/j.hoc.2020.09.003_bib117","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.09.003_bib118","doi-asserted-by":"crossref","first-page":"9531","DOI":"10.1200\/JCO.2019.37.15_suppl.9531","article-title":"The anti\u2013PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600\u2013mutant melanoma: updated efficacy and safety from parts 1 and 2 of COMBI-i","volume":"37","author":"Long","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2020.09.003_bib119","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2020.09.003_bib120","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.003_bib121","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.19.01381","article-title":"Phase III study of adjuvant ipilimumab (3 or 10\u00a0mg\/kg) versus high-dose interferon Alfa-2b for resected high-risk melanoma: North American Intergroup E1609","volume":"38","author":"Tarhini","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2020.09.003_bib122","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2020.09.003_bib123","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib124","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, <em>BRAF<\/em>V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2020.09.003_bib125","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.09.003_bib126","doi-asserted-by":"crossref","first-page":"v543","DOI":"10.1093\/annonc\/mdz255.022","article-title":"1333P - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib\u00a0+ trametinib (D\u00a0+ T) in the metastatic and adjuvant setting","volume":"30","author":"Grob","year":"2019","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2020.09.003_bib127","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses","volume":"24","author":"Moschos","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.003_bib128","doi-asserted-by":"crossref","first-page":"e87705","DOI":"10.1371\/journal.pone.0087705","article-title":"Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab","volume":"9","author":"Tarhini","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.hoc.2020.09.003_bib129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40425-018-0428-5","article-title":"Neoadjuvant ipilimumab (3\u00a0mg\/kg or 10\u00a0mg\/kg) and high dose IFN-\u03b12b in locally\/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire","volume":"6","author":"Tarhini","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.003_bib130","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.hoc.2020.09.003_bib131","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2020.09.003_bib132","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.003_bib133","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A\u00a0single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.hoc.2020.09.003_bib134","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2020.09.003_bib135","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2019.37.15_suppl.9503","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"37","author":"Menzies","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.003_bib136","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2217\/fon-2019-0666","article-title":"KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma","volume":"16","author":"Luke","year":"2020","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2020.09.003_bib137","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cncr.32585","article-title":"Considering adjuvant therapy for stage II melanoma","volume":"126","author":"Poklepovic","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2020.09.003_bib138","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cncr.22427","article-title":"Chemotherapy for metastatic melanoma","volume":"109","author":"Gogas","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2020.09.003_bib139","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2020.09.003_bib140","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820301179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:15:29Z","timestamp":1760184929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820301179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0889858820301179"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.09.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State of Melanoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}